Literature DB >> 17635179

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

Christa E Flück1, Catherine Nicolo, Amit V Pandey.   

Abstract

Cytochrome P450 proteins are involved in metabolism of drugs and xenobiotics. In the endoplasmic reticulum a single nicotinamide adenine dinucleotide phosphate (NADPH) P450 oxidoreductase (POR) supplies electrons to all microsomal P450s for catalytic activity. POR is a flavoprotein that contains both flavin mononucleotide and flavin adenine dinucleotide as cofactors and uses NADPH as the source of electrons. We have recently reported a number of POR mutations in the patients with disordered steroidogenesis. In the first report we had described missense mutations (A287P, R457H, V492E, C569Y, and V608F) identified in four patients with defects in steroid production. Each POR variant was produced as recombinant N-27 form of the enzyme in bacteria and as full-length form in yeast. Membranes from bacteria or yeast expressing normal or variant POR were purified and their activities were characterized in cytochrome c and CYP17A1 assays. Later we have published a larger study that described a whole range of POR mutations and characterized the mutants/polymorphisms A115V, T142A, M263V, Y459H, A503V, G539R, L565P, R616X, V631I, and F646del from the sequencing of patient DNA. We also studied POR variants Y181D, P228L, R316W, G413S, and G504R that were available in public databases or published literature. Three-dimensional structure of rat POR is known and we have used this structure to deduce the structure-function correlation of POR mutations in human. The missense mutations found in patients with disordered steroidogenesis are generally in the co-factor binding and functionally important domains of POR and the apparent polymorphisms are found in regions with lesser structural importance. A variation in POR can alter the activity of all microsomal P450s, and therefore, can affect the metabolism of drugs and xenobiotics even when the P450s involved are otherwise normal. It is important to study the genetic and biochemical basis of POR variants in human population to gain information about possible differences in P450 mediated reactions among the individuals carrying a variant or polymorphic form of POR that could impact their metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635179     DOI: 10.1111/j.1472-8206.2007.00520.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  17 in total

1.  Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing : Overall analysis of a female with POR deficiency.

Authors:  Tao Zhang; Zhou Li; Xinling Ren; Bo Huang; Guijin Zhu; Wei Yang; Lei Jin
Journal:  J Assist Reprod Genet       Date:  2020-07-28       Impact factor: 3.412

2.  Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients.

Authors:  Chengxian Guo; Q I Pei; Hongyi Tan; Zhijun Huang; Hong Yuan; Guoping Yang
Journal:  Biomed Rep       Date:  2014-12-02

3.  Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort.

Authors:  Mária Tomková; Satya Prakash Panda; Ondřej Šeda; Alice Baxová; Martina Hůlková; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

4.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

5.  Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.

Authors:  Georgia Ragia; Vana Kolovou; Anna Tavridou; Laure Elens; Alexandros D Tselepis; Moses Elisaf; Ron H N Van Schaik; Genovefa Kolovou; Vangelis G Manolopoulos
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

6.  NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.

Authors:  David S Riddick; Xinxin Ding; C Roland Wolf; Todd D Porter; Amit V Pandey; Qing-Yu Zhang; Jun Gu; Robert D Finn; Sebastien Ronseaux; Lesley A McLaughlin; Colin J Henderson; Ling Zou; Christa E Flück
Journal:  Drug Metab Dispos       Date:  2012-10-19       Impact factor: 3.922

7.  Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.

Authors:  Xuan Chen; Li Qiang Pan; Hua Naranmandura; Su Zeng; Shu Qing Chen
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

8.  Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche.

Authors:  Jan Idkowiak; Ewa M Malunowicz; Vivek Dhir; Nicole Reisch; Maria Szarras-Czapnik; Donna M Holmes; Cedric H L Shackleton; John D Davies; Ieuan A Hughes; Nils Krone; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

Review 9.  Pharmacogenomics of human P450 oxidoreductase.

Authors:  Amit V Pandey; Patrick Sproll
Journal:  Front Pharmacol       Date:  2014-05-09       Impact factor: 5.810

10.  Suppression of cytochrome p450 reductase enhances long-term hematopoietic stem cell repopulation efficiency in mice.

Authors:  Yan Zhang; Fang Dong; Na Zhang; Hui Cheng; Yakun Pang; Xiaomin Wang; Jing Xu; Xinxin Ding; Tao Cheng; Jun Gu; Weiping Yuan
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.